ANXA5 and Bjornstad syndrome: Specifically, at 72 h, a concentration-dependent maximal increase in %annexinV was observed in KMT2A-PTD patient samples following treatment with fadraciclib at 0.5 μM (20.5 ± 9.6%, p = 0.6051) and 1 μM (79.5 ± 12.9%, p < 0.0001), and in KMT2A WT patient samples following treatment with fadraciclib at 0.5 μM (33 ± 14.6%, p = 0.624) and 1 μM (74 ± 26%, p < 0.0001) compared with NDC (Fig. 3A).